Amgen Exec Says Looking Forward To Data From Experimental Weight Loss Drug's Mid-Stage Trial Next Year
Portfolio Pulse from Benzinga Newsdesk
An executive from Amgen has stated that they are looking forward to the data from the mid-stage trial of their experimental weight loss drug, which is expected next year.
October 31, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Amgen is expecting data from the mid-stage trial of their experimental weight loss drug next year. This could potentially impact the company's stock depending on the results of the trial.
The results of the mid-stage trial could potentially have a significant impact on Amgen's stock. Positive results could lead to an increase in the stock's value, while negative results could lead to a decrease. However, as the results are not yet known, the impact is currently neutral.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100